首页> Cancer cell> KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer.

KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer.

导出 LinkOut

翻译打印收藏纠错

第一作者： Ana,Galan-Cobo

第一单位： Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

作者： Ana,Galan-Cobo ^[1] ; Natalie I,Vokes ^[1] ; Yu,Qian ^[1] ; David,Molkentine ^[1] ; Kavya,Ramkumar ^[1] ; Alvaro G,Paula ^[1] ; Marlese,Pisegna ^[1] ; Daniel J,McGrail ^[2] ; Alissa,Poteete ^[1] ; Sungnam,Cho ^[1] ; Minh Truong,Do ^[1] ; Amirali,Karimi ^[1] ; Yifan,Kong ^[1] ; Anisha,Solanki ^[3] ; Ankur,Karmokar ^[3] ; Nicolas,Floc'h ^[3] ; Adina,Hughes ^[3] ; Rebecca,Sargeant ^[4] ; Lucy,Young ^[3] ; Li,Shen ^[5] ; Gozde,Kar ^[3] ; Caezaan,Keshvani ^[6] ; Claudio,Arrechedera ^[7] ; Sharia,Hernandez ^[7] ; Katharina,Schlacher ^[6] ; Jing,Wang ^[5] ; Sonia,Iyer ^[8] ; James,Conway ^[9] ; Mohamed Reda,Keddar ^[10] ; Marta,Milo ^[10] ; Ilario,de Toma ^[11] ; Susan E,Critchlow ^[3] ; J Carl,Barrett ^[8] ; Jan,Cosaert ^[3] ; Alan,Lau ^[3] ; Viia,Valge-Archer ^[3] ; Lauren A,Byers ^[1] ; Simon T,Barry ^[3] ; John V,Heymach ^[12]

作者单位： Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ^[1] Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, USA. ^[2] Early Oncology R&D, AstraZeneca, Cambridge, UK. ^[3] Imaging Sciences, CPSS, AstraZeneca, Cambridge, UK. ^[4] Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ^[5] Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ^[6] Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ^[7] Translational Medicine, Oncology R&D, AstraZeneca, Boston, MA, USA. ^[8] Oncology Data Science, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA. ^[9] Oncology Data Science, Oncology R&D, AstraZeneca, Cambridge, UK. ^[10] Early Oncology, Oncology R&D, AstraZeneca, Barcelona, Spain. ^[11] Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: jheymach@mdanderson.org. ^[12]

关键词 ATR inhibition DDR KEAP1 LKB1 NSCLC STK11 ceralasertib immunotherapy lung cancer